– Phase 2a study of CTEV in coronary artery bypass grafting (CABG) is expected to start this quarter –
Other News
CIRCA Scientific Appoints Jack Darby as Chief Executive Officer to Accelerate Commercial Expansion of Cardiovascular Access Portfolio
Veteran cardiovascular medical device executive to lead Company’s next phase of growth as CIRCA builds a differentiated cardiovascular access portfolio; Lee Geist transitions to Chief Operating Officer ENGLEWOOD, Colo., July 24, 2026 /PRNewswire/ — CIRCA Scientific, Inc., a…
Magnendo Secures $18M Series A Financing to Transform Endovascular Access for Stroke Intervention
MIT spinout to accelerate product development and first-in-human studies of its magnetic robotic navigation platform designed to dramatically improve the s
Wellumio closes oversubscribed $9.75 million pre-Series A round to accelerate portable stroke imaging technology
Australian medtech investor Bioshore Ventures and US neurotechnology investor Jumpspace Ventures join Wellumio’s oversubscribed pre-Series A round in the final close, supporting the next phase of clinical validation and commercialisation WELLINGTON, New Zealand, July 24, 2026 – Wellumio, a New Zealand medical technology company developing Axana®, a portable brain imaging […]
Edwards Lifesciences Reports Second Quarter Results
IRVINE, Calif.–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2026. Highlights Q2 sales grew 13.6% to $1.74 billion1, constant currency2 sales grew 12.5% Q2 TAVR sales grew 11.3% to $1.26 billion1; constant currency2 sales grew 10.5% Q2 TMTT sales were $195.9 million1,3, driven by portfolio of repair and replacement therapies Q2 EPS of $0.421; adjusted2 EPS of $0.781 Recent clinical data at New York Valves reinforce best-in-clas
AtriCure Reports Second Quarter 2026 Financial Results
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2026 financial results. “Our team delivered healthy growth and a significant step up in profitability in the second quarter,” said Michael Carrel, President and Chief Executive Officer. “Our innovative technologies continue to prove their valu
Sentante’s CE-marked robotic platform is building the data foundation for endovascular physical AI
Drive-side force sensing and a 1:1 motion-mimicking interface make every procedure a training-grade record of expert clinical skill KAUNAS, Lithuania, July 23, 2026 /PRNewswire/ — Sentante, the medical robotics company building a haptic, device-agnostic platform for remote vascular…
Venus Medtech Announces Completion of Patient Enrollment in Pivotal China Trial for Venus-PowerX, the World’s First Fully Recoverable Self-Expanding Dry-Valve TAVR System
The PREVAILS study, now fully enrolled, marks a critical step toward simultaneous regulatory submissions in China and Europe for the next-generation TAVR system HANGZHOU, China, July 23, 2026 /PRNewswire/ — Venus Medtech (Hangzhou) Inc. (02500.HK) today announced that patient enrollment…
Ribo Discloses Positive Data from Vortosiran Phase 2a Trial – World’s First Clinical Data on siRNA-Mediated FXI Inhibition Following Multiple Dosing in Patients with Coronary Artery Disease
SHANGHAI and MOLNDAL, Sweden, July 22, 2026 /PRNewswire/ — Suzhou Ribo Life Science Co., Ltd. (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as “Ribo”) today announce at China Pharmaceutical Innovation Conference (CPIC) in Shanghai, the positive…
Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases
Collaboration combines Evogene’s AI-driven computational chemistry platform with ELEO’s proprietary biological capabilities to accelerate the discovery of novel oral therapies targeting a multi-billion-dollar cardiovascular market opportunity REHOVOT, Israel and DAEJEON, South Korea, July…
